Comparative Pharmacology
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus QUIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus QUIXIN.
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs QUIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Quixin (levofloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
500 mg or 750 mg intravenously once daily. Infusion over 60-90 minutes.
One to two drops in affected eye(s) every 2 hours while awake, up to 8 times daily for 7-14 days.
None Documented
None Documented
6-8 hours in patients with normal renal function (creatinine clearance >50 mL/min); increases to 20-48 hours in severe renal impairment (CrCl <20 mL/min); clinically relevant for dosing interval adjustment.
Terminal elimination half-life: 6–8 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours if CrCl <30 mL/min).
Renal: ~87% of dose excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5% eliminated as unchanged drug and metabolites; <4% recovered in feces.
Renal (approximately 70% unchanged in urine); biliary/fecal (~30%, partly as metabolites and unchanged drug).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic